SCHEMBL7610176

SCHEMBL7610176

C=C(CC)C(=O)NC(O)(O)O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28895183 0.81 RAB9A (0.34) TET2
SCHEMBL23637603 0.74 GAA (0.35)
SCHEMBL5673103 0.72
SCHEMBL1767666 0.72
SCHEMBL7936208 0.70
SCHEMBL9359207 0.70
SCHEMBL10910411 0.70 TDP1 (0.35)
SCHEMBL29573839 0.70 MEN1 (0.39)
SCHEMBL21716651 0.69 ALDH1A1 (0.41)
SCHEMBL8855259 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6359006-B2 ANTIISCHEMIC AGENTS; ANTICANCER AGENTS ALLIANCE PHARMACEUTICAL CORP. 2002-03-19 US disclosed
US-20020019442-A1 AMPHIPHILIC FLUORINE DERIVATIVES WITH TELOMERIC STRUCTURES; PREPARATION PROCEDURE AND BIOMEDICAL APPLICATIONS PFC THERAPEUTICS, LLC 2002-02-14 US disclosed
US-5847206-A Amphiphilic fluorine derivatives with telomeric structures; preparation procedure and biomedical applications ALLIANCE PHARMACEUTICAL CORP. (US) 1998-12-08 US disclosed
US-5703126-A USED AS MARKER, CARRIERS IN TRANSPORT OF GASES, CONTRAST AGENT, DRUG OR CARRIER FOR DRUG ALLIANCE PHARMACEUTICAL CORP. (US) 1997-12-30 US disclosed
US-5527962-A FLUOROPOLYMER WITH PERFLUOROALKYL MERCAPTAN END GROUP AS CARRIER FOR DRUG DELIVERY ALLIANCE PHARMACEUTICAL CORP. (US) 1996-06-18 US disclosed
EP-0548096-B1 AMPHIPHILIC FLUORINE DERIVATIVES WITH TELOMERIC STRUCTURES; PREPARATION AND BIOMEDICAL APPLICATIONS ATTA (FR) 1995-11-08 EP disclosed
EP-0548096-A1 AMPHIPHILIC FLUORINE DERIVATIVES WITH TELOMERIC STRUCTURES; PREPARATION AND BIOMEDICAL APPLICATIONS. ATTA (FR) 1993-06-30 EP disclosed
WO-1992002560-A1 AMPHIPHILIC FLUORINE DERIVATIVES WITH TELOMERIC STRUCTURES; PREPARATION AND BIOMEDICAL APPLICATIONS S.A. A.T.T.A. APPLICATIONS ET TRANSFERTS DE TECHNO (FR) 1992-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019442-A1 AMPHIPHILIC FLUORINE DERIVATIVES WITH TELOMERIC STRUCTURES; PREPARATION PROCEDURE AND BIOMEDICAL APPLICATIONS POT1, TERF2, TELO2 TET2 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.